U.S.-listed shares of HSBC Holdings Plc HSBA.L , HBC.N rose in active trade before Monday's opening bell after the world's second biggest bank reported first-half profits that beat forecasts.
Shares of HSBC, based in Britain and with operations around the globe, rose to $63.65 on Instinet, up from their New York Stock Exchange close of $61.36. In London trading, its shares rose to a 13-month high on Monday.
Shares of Cisco Systems Inc. CSCO.O , the world's largest maker of equipment that directs Internet traffic, also rose in pre-market trade. Shares of Cisco, which reports quarterly results on Tuesday, edged up to $19.39 on Instinet from their Friday close of $19.15.
Among decliners, shares of CV Therapeutics CTVX.O sank on Instinet after the biotechnology company said a U.S. Food and Drug Administration advisory panel review of its angina drug, Ranexa, scheduled for September, was canceled.
CV Therapeutics shares fell to $25 on Instinet, down from their Friday close of $35.18 on the Nasdaq. The company said in a statement that an advisory committee meeting in September would not provide sufficient time for the company and the FDA to complete analysis of the new drug application.
General Electric Co. GE.N edged lower on Instinet, down to $28.43 from its close of $28.46. The conglomerate was in final talks on Sunday to sell its slow-growing financial-guaranty insurance business for about $2.16 billion, slightly below book value, to a consortium led by PMI Group Inc., the Wall Street Journal reported on Monday.
Shares of HSBC, based in Britain and with operations around the globe, rose to $63.65 on Instinet, up from their New York Stock Exchange close of $61.36. In London trading, its shares rose to a 13-month high on Monday.
Shares of Cisco Systems Inc. CSCO.O , the world's largest maker of equipment that directs Internet traffic, also rose in pre-market trade. Shares of Cisco, which reports quarterly results on Tuesday, edged up to $19.39 on Instinet from their Friday close of $19.15.
Among decliners, shares of CV Therapeutics CTVX.O sank on Instinet after the biotechnology company said a U.S. Food and Drug Administration advisory panel review of its angina drug, Ranexa, scheduled for September, was canceled.
CV Therapeutics shares fell to $25 on Instinet, down from their Friday close of $35.18 on the Nasdaq. The company said in a statement that an advisory committee meeting in September would not provide sufficient time for the company and the FDA to complete analysis of the new drug application.
General Electric Co. GE.N edged lower on Instinet, down to $28.43 from its close of $28.46. The conglomerate was in final talks on Sunday to sell its slow-growing financial-guaranty insurance business for about $2.16 billion, slightly below book value, to a consortium led by PMI Group Inc., the Wall Street Journal reported on Monday.
3287.99
1275.09